Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial

2020 ◽  
Vol 7 (3) ◽  
pp. e218-e225 ◽  
Author(s):  
Shinya Kimura ◽  
Jun Imagawa ◽  
Kazunori Murai ◽  
Masayuki Hino ◽  
Toshio Kitawaki ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Phase 2 ◽  
First Line ◽  
Multicentre Phase ◽  
Phase 2 Trial ◽  
Treatment Free Remission

Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial

2021 ◽  
Vol 8 (12) ◽  
pp. e902-e911 ◽  
Author(s):  
Kazunori Murai ◽  
Hiroshi Ureshino ◽  
Takashi Kumagai ◽  
Hideo Tanaka ◽  
Kaichi Nishiwaki ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Older Patients ◽  
Low Dose ◽  
Chronic Phase ◽  
Phase 2 ◽  
Multicentre Phase ◽  
Phase 2 Trial

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial

2015 ◽  
Vol 16 (4) ◽  
pp. 457-464 ◽  
Author(s):  
Patricia Pautier ◽  
Anne Floquet ◽  
Christine Chevreau ◽  
Nicolas Penel ◽  
Cécile Guillemet ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Line Treatment ◽  
Phase 2 ◽  
First Line ◽  
Multicentre Phase ◽  
Phase 2 Trial ◽  
First Line Treatment

scholarly journals Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study

2015 ◽  
Vol 2 (9) ◽  
pp. e376-e383 ◽  
Author(s):  
Preetesh Jain ◽  
Hagop Kantarjian ◽  
Elias Jabbour ◽  
Graciela Nogueras Gonzalez ◽  
Gautam Borthakur ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Chronic Phase ◽  
Line Treatment ◽  
Phase 2 ◽  
First Line ◽  
Phase 2 Study ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document